REGISTER
SIGN IN
Biocard Malaria PfPv Lateral Flow Assay Kit
MPIN: MP41055
Sign in to view price
Biocard™ Malaria Pf/Pv Lateral flow assay kit is a Rapid sandwich test kit for differential detection of Malaria P.falciparum and P.vivax species by HRP-2 and pLDH antigen capture.All the accessories needed for the sampling and testing are included.Works on Human Whole blood.Results can be obtained in 20 minutes
Ask for Quote
Biocard™ Malaria Pf/Pv Lateral flow assay kit is a Rapid sandwich test kit for differential detection of Malaria P.falciparum and P.vivax species by HRP-2 and pLDH antigen capture.All the accessories needed for the sampling and testing are included.Works on Human Whole blood.Results can be obtained in 20 minutes.
Features
- Sample Type: Human Whole blood.
- Ability to differentially detect P.falciparum and P.vivax by antigen capture assay in Human whole blood.
- Convenient pack sizes
- Simple to perform
- Results can be obtained in 20 minutes
- Needs no equipment
- Excellent sensitivity and specificity.
- Convenient storage between 4-30°C.
- ISO -13485 2012 and GMP compliant manufacturing process.
Specification
Biocard™ Malaria Pf Pv Lateral Flow Assay Kit
Related products
-
Laboratory Infrastructure
Neoscreen Biotinidase
Labsystems Diagnostics’ Neonatal Toxoplasma gondii IgM FEIA is a fluorometric enzyme immunoassay intended for the determination of IgM-class antibodies to Toxoplasma gondii in blood samples dried on filter paper. The test is intended as a primary method for screening newborns for congenital toxoplasmosis (CT).
SKU: MP40993 -
Laboratory Infrastructure
Neoscreen IRT
Cystic Fibrosis (CF) is an autosomal recessive disorder affecting the lungs, pancreas, intestine and liver. CF is the most common in Caucasians with an incidence rate 1:2500 newborns. CF is caused by mutation in the gene for the protein cystic fibrosis transmembrane conductance regulator (CTFR) [1,2]. Large-scale neonatal screening for CF is performed by indentification of increased levels of immunoreactive trypsinogen (IRT) in blood.
SKU: MP40991 -
Laboratory Infrastructure
Neoscreen G6PD
Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency is the most common human enzyme deficiency; an estimated 400 million people worldwide are affected by this enzymopathy (6). With regards to the demographics of G6PD deficiency, most of the affected individuals reside in Africa, the Middle East, and Southeast Asia. The G6PD enzyme catalyzes an oxidation/reduction reaction.
SKU: MP40989 -
Laboratory Infrastructure
Neoscreen Galactose
Galactosemia is an inherited metabolic abnormality comprising three distinctive clinical entities of the galactose pathway defects. Classic galactosemia is due to -Dgalactose- 1-phosphate-uridyl-transferase (GALT) defect (1). The test principle is based on extraction of Galactose & Galactose-1-phosphate from dried blood spot followed by enzymatic conversion of Galactose-1-phosphate & Galactose. Two kinds of extraction methods (acidic and heat) can be used for extraction step.
SKU: MP40990
